WO1990008549A1 - N-acetylglucosamin-zubereitungen zur buccalen anwendung - Google Patents
N-acetylglucosamin-zubereitungen zur buccalen anwendung Download PDFInfo
- Publication number
- WO1990008549A1 WO1990008549A1 PCT/DE1989/000567 DE8900567W WO9008549A1 WO 1990008549 A1 WO1990008549 A1 WO 1990008549A1 DE 8900567 W DE8900567 W DE 8900567W WO 9008549 A1 WO9008549 A1 WO 9008549A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acetylglucosamine
- diseases
- joints
- degenerative
- therapy
- Prior art date
Links
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 title claims abstract description 31
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 title claims abstract description 31
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 title claims abstract description 31
- 229950006780 n-acetylglucosamine Drugs 0.000 title claims abstract description 31
- 238000002360 preparation method Methods 0.000 title abstract description 9
- 201000010099 disease Diseases 0.000 claims abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 10
- 230000003412 degenerative effect Effects 0.000 claims abstract description 6
- 208000027866 inflammatory disease Diseases 0.000 claims abstract description 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract 3
- 239000003826 tablet Substances 0.000 claims description 12
- 210000000214 mouth Anatomy 0.000 claims description 8
- 238000002560 therapeutic procedure Methods 0.000 claims description 5
- 230000001055 chewing effect Effects 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000000969 carrier Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000007493 shaping process Methods 0.000 claims 1
- 230000000087 stabilizing effect Effects 0.000 claims 1
- 210000002808 connective tissue Anatomy 0.000 abstract 1
- MTDHILKWIRSIHB-UHFFFAOYSA-N (5-azaniumyl-3,4,6-trihydroxyoxan-2-yl)methyl sulfate Chemical compound NC1C(O)OC(COS(O)(=O)=O)C(O)C1O MTDHILKWIRSIHB-UHFFFAOYSA-N 0.000 description 7
- 229920002683 Glycosaminoglycan Polymers 0.000 description 7
- 229960002849 glucosamine sulfate Drugs 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 5
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 5
- 229960002442 glucosamine Drugs 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 150000002337 glycosamines Chemical class 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000000845 cartilage Anatomy 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000001364 causal effect Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000012153 long-term therapy Methods 0.000 description 3
- 239000007937 lozenge Substances 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 201000008482 osteoarthritis Diseases 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 241000699800 Cricetinae Species 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 239000005445 natural material Substances 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001179 synovial fluid Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 244000303965 Cyamopsis psoralioides Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- -1 N-acetylglucosamine Chemical class 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000005786 degenerative changes Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000002301 glucosamine derivatives Chemical class 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000007788 roughening Methods 0.000 description 1
- 239000011833 salt mixture Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the joints of humans and vertebrates are extraordinarily strong, changeable and sometimes exposed to one-sided loads due to civilization.
- Very smooth surfaces of the bones on the articular surfaces, the excellent lubricity of the synovial fluid, as well as elastic but mechanically strong cartilage and ligaments ensure that the joints function properly, especially in adolescence.
- Degenerative processes in the most stressed joints, knees and hips and the spine can already be observed in middle age, which in many cases also lead to clinically relevant complaints.
- Such changes primarily concern the quality of the synovial fluid and the cartilage, in later stages roughening and erosion on the bones themselves can be observed. This can result in pain and restrictions on the ability to move up to complete stiffening of the joints.
- the process of damage to the joints can be intensified by many external influences: carrying heavy loads, unfavorable posture, complete lack of exercise, excessive sports, etc. Furthermore, improper nutrition, metabolic diseases, infections, rheumatic diseases etc. can progress rapidly contribute to degenerative joint diseases or get them going.
- the therapy of the painful, sometimes inflammatory conditions is often only symptomatic with the help of non-steroidal anti-inflammatory drugs such as indomethacin or even by using corticoids. Both groups of therapeutic agents cause serious side effects and should therefore be used as little as possible.
- non-steroidal anti-inflammatories and with the corticoids there is a risk of a further shift in the metabolism of the glycosaminoglycans (GAGs) in the direction of accelerated degradation.
- GAGs glycosaminoglycans
- glycosaminoglycans or the precursor of a GAG building block, glucosamine have a causal therapeutic effect.
- the effect is based on the one hand on the incorporation of the relevant building blocks into the GAGs, on the other hand on stimulating the new synthesis of GAGs by increasing the concentration of precursors of their synthesis.
- glucosamine sulfate was also administered orally, intramuscularly and intra-articularly, with good therapeutic success.
- the great advantage of glucosamine sulfate is that it is a compound that can be clearly defined in terms of identity, purity and stability.
- glucosamine sulfate does not cause allergies and, in the necessary dosage, hardly any toxic effects are expected.
- glucosamine sulfate also has significant disadvantages, as can be seen, for example, from the basic information Dona J 200-S from the company Schwiermann-Arzneistoff, 5060 Bergisch Gladbach 2:
- the oral form of administration is obviously much less effective than intravenous or intramuscular injection.
- An oral weekly dose of 5250 mg is recommended, whereas parenterally only 1200 mg are necessary.
- the more effective injection preparation is not sufficiently stable in solution at a physiological pH; it is therefore prepared, stored and supplied at an acidic pH and must be neutralized by the doctor before use.
- a buffer solution is added to the glucosamine sulfate solution.
- glucosamine sulfate solution and buffer have an osmotic pressure that is so high compared to the blood that lidocaine must also be added as a local anesthetic. Only with this addition does the injection into the joints become sufficiently painless.
- Glucosamine and the low chemical stability were tried to counteract by using specific salts and salt mixtures.
- the effectiveness of glucosamine could be somewhat improved by using mixtures of the sulfate and hydroiodide (Rovaki, 1968, US Patent 36 83 076).
- Senin et al., 1981 produced special mixed crystals from NaCl and glucosamine sulfate, which are said to be particularly less hygroscopic and sufficiently stable (DOS 32 15 844 A 1). However, the taste is said to be very bitter.
- N-acetylglucosamine has the advantage of being stable and, at least after parenteral administration, of being undoubtedly effective against degenerative joint diseases. 5
- N-acetylglucosamine has a surprisingly good, not too strong, purely sweet taste. Despite the relatively high molecular weight and the very hydrophilic character of the molecule, some of the active ingredient is already absorbed in the oral cavity. This prevents degradation in the intestinal mucosa and liver before reaching the general circulation.
- N-acetylglucosamine is more bioavailable and effective when taken orally if it is kept in the mouth for as long as possible and remains in contact with the mucous membranes. This can be achieved in a very simple way: Already at
- Part of the granules can be resorbed in the oral cavity if not immediately rinsed with liquid.
- N-acetylglucosamine for buccal administration can be used in a daily dose of 50 mg to 1000 mg. Higher doses are possible due to the very good tolerance, 200 mg - 600 mg / day are preferred.
- the single dose can contain 10 mg to 500 mg of N-acetylglucosamine if taken several times a day, preferably 50 mg to 250 mg.
- auxiliaries are e.g. B. sugar and related substances (sucrose, lactose, glucose, mannitol, sorbitol, fructose etc.), swelling substances (agar, gum arabic, guar, gelatin etc.), starch, dextrans, dextrins, flavorings and flavorings (citric acid, tartaric acid, Ascorbic acid, peppermint oil etc.), buffer salts, solubilizers.
- sugar and related substances sucrose, lactose, glucose, mannitol, sorbitol, fructose etc.
- swelling substances agar, gum arabic, guar, gelatin etc.
- starch starch
- dextrans dextrins
- flavorings and flavorings citric acid, tartaric acid, Ascorbic acid, peppermint oil etc.
- buffer salts solubilizers.
- Powder, granules and preferably tablets or all forms for sucking and chewing are suitable as forms.
- N-acetylglucosamine 2500 g are mixed homogeneously with 1000 g of lactose and 15 g of magnesium stearate, granulated and compressed into tablets under high pressure. Individual weight of one tablet 351.5 mg content of N-acetylglucosmin per tablet: 250 mg intake before meals, slowly dissolve one tablet in the mouth.
- N-acetylglucosamine 2500 g are mixed homogeneously with 250 g of citric acid and 100 g of polyvinylpyrrolidone, slightly moistened with 80% ethanol, mixed into tablets O 90/08549
- N-acetylglucosamine 2500 g are mixed homogeneously with 100 g of ascorbic acid to improve the taste, 100 g of polyvinylpyrrolidone and 1000 g of corn starch, granulated with 80% ethanol to give a paste and sieved through a sieve with a mesh size of 0.5-1 mm.
- ganulate containing approximately 100 mg of N-acetylglucosamine are placed on a spoon 5 with a measuring cup and slowly dissolved in the mouth some time before meals. It is not rinsed with liquid.
- Fig. 2 compares graphically the plasma levels in hamsters following intragastric (peroral) and buccal Ver ⁇ abjectung of 2 ml of an aqueous solution of 200 mg N-acetyl g ⁇ tylglucosamin.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1508947A JPH07103033B2 (ja) | 1989-01-26 | 1989-08-28 | 経口投与のためのｎ―アセチルグルコサミン製剤 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US302,403 | 1989-01-26 | ||
| US07/302,403 US4870061A (en) | 1986-01-29 | 1989-01-26 | Use of N-acetylglucosamine for the therapy of degenerative joint disease and related diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1990008549A1 true WO1990008549A1 (de) | 1990-08-09 |
Family
ID=23167604
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/DE1989/000567 WO1990008549A1 (de) | 1989-01-26 | 1989-08-28 | N-acetylglucosamin-zubereitungen zur buccalen anwendung |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP0379753B1 (enrdf_load_stackoverflow) |
| JP (1) | JPH07103033B2 (enrdf_load_stackoverflow) |
| AT (1) | ATE82127T1 (enrdf_load_stackoverflow) |
| DE (2) | DE3927723A1 (enrdf_load_stackoverflow) |
| ES (1) | ES2052893T3 (enrdf_load_stackoverflow) |
| GR (1) | GR3006815T3 (enrdf_load_stackoverflow) |
| WO (1) | WO1990008549A1 (enrdf_load_stackoverflow) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1067246C (zh) * | 1996-12-27 | 2001-06-20 | 中国人民解放军第三军医大学 | N－乙酰－d－氨基葡萄糖在制备治疗皮肤癣菌的药物中的应用 |
| CN1067245C (zh) * | 1996-12-27 | 2001-06-20 | 中国人民解放军第三军医大学 | N－乙酰－d－氨基葡萄糖在制备治疗呼吸道疾病的药物中的应用 |
| EP1140171A4 (en) * | 1998-12-15 | 2002-03-13 | Brigham & Womens Hospital | METHODS AND PRODUCTS FOR REGULATING THE COMPLEMENT ACTIVATION ASSOCIATED WITH THE LECTIN COMPLEMENT SYSTEM |
| CN1095366C (zh) * | 1996-12-27 | 2002-12-04 | 中国人民解放军第三军医大学 | N－乙酰－d－氨基葡萄糖在制备治疗肠道疾病药物中的应用 |
| WO2004084915A1 (fr) | 2003-03-27 | 2004-10-07 | Third Military Medical University, Chinese People's Liberation Army, P.R. Of China | Utilisation de n-acetyl-d-aminoglycosamine dans le traitement d'inflammations non specifiques associees a des facteurs physiques ou chimiques |
| WO2004084916A1 (fr) * | 2003-03-27 | 2004-10-07 | Third Military Medical University, Chinese People's Liberation Army, P.R. Of China | Utilisation de n-acetyle-d-aminoglycosamine dans le traitement de lesions locales et de symptomes systematiques lies aux infections virales ou bacteriennes |
| US7273925B1 (en) | 1998-12-15 | 2007-09-25 | Brigham And Women's Hospital, Inc. | Methods and products for regulating lectin complement pathway associated complement activation |
| US8524453B2 (en) | 2006-02-10 | 2013-09-03 | The Brigham And Woman's Hospital, Inc. | Lectin complement pathway assays and related compositions and methods |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9003614L (sv) * | 1990-11-13 | 1992-05-14 | Kurt G I Nilsson | Kosmetisk produkt |
| AU2003227681A1 (en) * | 2002-04-26 | 2003-11-10 | Novartis Ag | Method for treating inflammatory disorders |
| CN1232256C (zh) * | 2003-03-27 | 2005-12-21 | 中国人民解放军第三军医大学 | N－乙酰氨基葡萄糖在制备治疗自身免疫反应所致的局部损伤或全身症状的药物中的应用 |
| WO2005034961A1 (en) * | 2003-10-01 | 2005-04-21 | Optimer Pharmaceuticals, Inc. | Treatment of a condition in a mammal with adminisration of aminosugar and uses thereof |
| US20070082851A1 (en) * | 2003-11-24 | 2007-04-12 | Optimer Pharmaceuticals Inc. | Treatment of a condition in a mammal with administration of Compounds and Methods of Use |
| TWI354559B (en) * | 2004-12-27 | 2011-12-21 | Yaizu Suisankagaku Ind Co Ltd | Oral disintegrative n-acetylglucosamine tablet and |
| JP5587543B2 (ja) * | 2008-02-06 | 2014-09-10 | サントリーホールディングス株式会社 | グルコサミンを含有する経口投与用固形製剤 |
| KR101098581B1 (ko) * | 2009-01-09 | 2011-12-26 | 서울대학교산학협력단 | Ａｂｈ 항원을 이용한 염증질환 개선용 조성물 |
| WO2010144943A1 (en) * | 2009-05-20 | 2010-12-23 | Ozpharma Pty Ltd | Buccal and/or sublingual therapeutic formulation |
| JP6270362B2 (ja) * | 2013-07-17 | 2018-01-31 | 日本水産株式会社 | 関節痛改善剤 |
| JP6940356B2 (ja) * | 2017-09-29 | 2021-09-29 | 株式会社ファンケル | Ｎ−アセチルグルコサミン錠剤 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2016182A1 (enrdf_load_stackoverflow) * | 1968-08-22 | 1970-05-08 | Rotta Research Lab | |
| EP0178602A2 (en) * | 1984-10-18 | 1986-04-23 | Peritain, Ltd. | Treatment for tissue degenerative inflammatory disease |
| DE3602670A1 (de) * | 1986-01-29 | 1987-07-30 | Speck Ulrich | Verwendung von n-acetylglucosamin zur therapie degenerativer gelenkprozesse und verwandter erkrankungen |
-
1989
- 1989-08-19 DE DE3927723A patent/DE3927723A1/de not_active Withdrawn
- 1989-08-28 WO PCT/DE1989/000567 patent/WO1990008549A1/de unknown
- 1989-08-28 DE DE8989250020T patent/DE58902712D1/de not_active Expired - Fee Related
- 1989-08-28 ES ES89250020T patent/ES2052893T3/es not_active Expired - Lifetime
- 1989-08-28 AT AT89250020T patent/ATE82127T1/de not_active IP Right Cessation
- 1989-08-28 EP EP89250020A patent/EP0379753B1/de not_active Expired - Lifetime
- 1989-08-28 JP JP1508947A patent/JPH07103033B2/ja not_active Expired - Lifetime
-
1993
- 1993-01-15 GR GR930400070T patent/GR3006815T3/el unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2016182A1 (enrdf_load_stackoverflow) * | 1968-08-22 | 1970-05-08 | Rotta Research Lab | |
| EP0178602A2 (en) * | 1984-10-18 | 1986-04-23 | Peritain, Ltd. | Treatment for tissue degenerative inflammatory disease |
| DE3602670A1 (de) * | 1986-01-29 | 1987-07-30 | Speck Ulrich | Verwendung von n-acetylglucosamin zur therapie degenerativer gelenkprozesse und verwandter erkrankungen |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1067246C (zh) * | 1996-12-27 | 2001-06-20 | 中国人民解放军第三军医大学 | N－乙酰－d－氨基葡萄糖在制备治疗皮肤癣菌的药物中的应用 |
| CN1067245C (zh) * | 1996-12-27 | 2001-06-20 | 中国人民解放军第三军医大学 | N－乙酰－d－氨基葡萄糖在制备治疗呼吸道疾病的药物中的应用 |
| CN1095366C (zh) * | 1996-12-27 | 2002-12-04 | 中国人民解放军第三军医大学 | N－乙酰－d－氨基葡萄糖在制备治疗肠道疾病药物中的应用 |
| EP1140171A4 (en) * | 1998-12-15 | 2002-03-13 | Brigham & Womens Hospital | METHODS AND PRODUCTS FOR REGULATING THE COMPLEMENT ACTIVATION ASSOCIATED WITH THE LECTIN COMPLEMENT SYSTEM |
| US7273925B1 (en) | 1998-12-15 | 2007-09-25 | Brigham And Women's Hospital, Inc. | Methods and products for regulating lectin complement pathway associated complement activation |
| WO2004084915A1 (fr) | 2003-03-27 | 2004-10-07 | Third Military Medical University, Chinese People's Liberation Army, P.R. Of China | Utilisation de n-acetyl-d-aminoglycosamine dans le traitement d'inflammations non specifiques associees a des facteurs physiques ou chimiques |
| WO2004084916A1 (fr) * | 2003-03-27 | 2004-10-07 | Third Military Medical University, Chinese People's Liberation Army, P.R. Of China | Utilisation de n-acetyle-d-aminoglycosamine dans le traitement de lesions locales et de symptomes systematiques lies aux infections virales ou bacteriennes |
| US8524453B2 (en) | 2006-02-10 | 2013-09-03 | The Brigham And Woman's Hospital, Inc. | Lectin complement pathway assays and related compositions and methods |
Also Published As
| Publication number | Publication date |
|---|---|
| EP0379753A1 (de) | 1990-08-01 |
| ATE82127T1 (de) | 1992-11-15 |
| JPH04502758A (ja) | 1992-05-21 |
| JPH07103033B2 (ja) | 1995-11-08 |
| ES2052893T3 (es) | 1994-07-16 |
| DE3927723A1 (de) | 1990-08-02 |
| DE58902712D1 (de) | 1992-12-17 |
| EP0379753B1 (de) | 1992-11-11 |
| GR3006815T3 (enrdf_load_stackoverflow) | 1993-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0379753B1 (de) | N-Acetylglucosamin-Zubereitungen zur buccalen Anwendung | |
| DE69520768T2 (de) | Pharmazeutische Zubereitungen, die Fluoxetin enthalten | |
| DE69532031T2 (de) | Schilddrüsenhormone enthaltende mittel | |
| DE69611369T2 (de) | Sublingual oder bukkal verabreichte arzneistoffe mit gesteuerter freisetzung | |
| DE60024491T2 (de) | Schnell-wirkende, gefrier-trocknete, orale, pharmazeutische formulierung für die behandlung von migräne | |
| EP0234207A2 (de) | Verwendung von N-Acetylglucosamin zur Therapie degenerativer Gelenkprozesse und verwandter Erkrankungen | |
| DE69628415T3 (de) | Arzneimittel enthaltend monoaminooxidase-b-hemmer | |
| KR101490721B1 (ko) | 감칠맛을 가진 디페리프론용 액상 제제 | |
| EP1067905A1 (de) | Brauseformulierungen | |
| EP0435913B1 (de) | Brausetablette | |
| EP1165081B1 (de) | Verfahren zum herstellen tolperison-enthaltender pharmazeutischer zubereitungen zur oralen verabreichung | |
| DE69119217T2 (de) | Zusammensetzungen zur kontrollierten freigabe | |
| WO2010009961A1 (de) | Pharmazeutische formulierung zur behandlung des oberen verdauungstraktes | |
| EP0471967B1 (de) | Sucralfat-Kautablette | |
| DE69913116T2 (de) | Orale flüssige lösung enthaltend das antidepressivum mirtazapine | |
| DE102005009240A1 (de) | Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften | |
| DE60225686T2 (de) | Paracetamol enthaltende tablette | |
| WO1999055342A1 (de) | Isomalt als wirkstoff enthaltendes erkältungsmittel | |
| DE60013466T2 (de) | Im mund zerfallende zusammensetzung mit mirtazapin | |
| WO2014161811A1 (de) | Lutschtablette zur behandlung von halsschmerz, heiserkeit und assoziiertem trockenen husten, sowie entzündlichen erkrankungen des mund und rachenraums | |
| DE2519528C2 (enrdf_load_stackoverflow) | ||
| EP1135147B1 (de) | Verfahren zur herstellung von arzneimitteln in fester darreichungsform aus pflanzlichen extrakten | |
| EP1150660B1 (de) | Pharmazeutische, metamizol enthaltende brauseformulierung | |
| KR101297354B1 (ko) | 안정하고 불쾌한 맛이 차폐된 덱시부프로펜을 함유한 투명한 시럽 조성물 | |
| DE202023103619U1 (de) | Darreichungsform auf Basis von Pflanzenextrakten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): JP |